UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 Commission file number: 001-39630 MOONLAKE IMMUNOTHERAPEUTICS (Exact Name of Registrant as Specified in Its Charter) (IRS Employer Identification No.) Cayman Islands 98-1711963 (State or Other Jurisdiction of Incorporation) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECUR ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

PresentationMatthias BodenstedtChief Financial Officer Good morning, good afternoon. Thank you so much for joining our Investor Day today, MoonLake Immunotherapeutics. My name is Matthias Bodenstedt, I'm the CFO of the company. And I'm sitting here on the right, Dr. Jorge Santos da Silva, our Chief Executive Officer; and Professor Kristian Reich, our Chief Scientific Officer. Together, we are very excited to walk you through a number of updates about the company. I will start with a very brief introduction, ...

Panama officially scraps CK Hutchison contracts, handing canal ports to Maersk | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]Item 1 of 4 A drone view shows Panama Ports Company (PPC) after Panama's Official Gazette published a court ruling formally annulling Hong Kong's CK Hutchison Holdings concessions for two ports along its strategic canal, after ruling late January the contracts violated the constitution, in Panama City, Pana ...

Axial Spondyloarthritis is a chronic, immune-mediated inflammatory disease mainly affecting the spine and sacroiliac joints, often causing chronic back pain, stiffness, and potential spinal fusion.Chronic Back Pain StudyIn the Phase 2 S-OLARIS trial, 81% of patients treated with sonelokimab achieved a clinically meaningful response at Week 12, demonstrating significant improvement in key disease parameters.The trial also confirmed the drug’s ability to reduce inflammation and osteoblast activity in affected ...

MoonLake Immunotherapeutics (NasdaqCM:MLTX) 2026 Investor Day February 23, 2026 08:00 AM ET Company ParticipantsJorge Santos da Silva - CEOJulian Harrison - Managing DirectorKristian Reich - Co-Founder and CSOMatthias Bodenstedt - CFOYun Zhong - SVP of Equity ResearchConference Call ParticipantsBrian Abrahams - Biotechnology Analyst and Global Sector Head of Healthcare ResearchKaveri Pohlman - Managing Director and Senior Equity Research AnalystPrakhar Agarwal - Senior Biotech AnalystThom Smith - Senior Man ...

Investor Day February 23rd, 2026 MoonLake Immunotherapeutics © 2026 | Proprietary | MoonLake TX Welcome to our Investor Day Date: February 23rd, 2026 Time: 8.00 am EST Agenda | Topic | Sub-topics | Speaker | Timing | | --- | --- | --- | --- | | Introduction | Welcome | Matthias | 10 mins | | | MLTX & SLK summary | | | | | Key points for the session | | | | axSpA update | axSpA market update | Kristian | 20 mins | | | S-OLARIS program overview | | | | | Efficacy & safety overview | | | | HS and FDA | FDA upd ...

Exhibit 99.1 MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results ZUG, Switzerland, February 22, 2026 – MoonLake Immunotherapeutics (NASDAQ:MLTX) ("MoonLake" or the "Company"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announces topline results from the S-OLARIS Phase 2 trial of SLK in patients with radiographic and non-radiographic axSpA ...

Group 1 - MoonLake Immunotherapeutics announced topline results from the S-OLARIS Phase 2 trial of sonelokimab (SLK) in patients with axial spondyloarthritis (axSpA), demonstrating significant clinical benefits [2][5][6] - In the S-OLARIS trial, 81% of patients treated with SLK achieved an ASAS40 response at Week 12, indicating a clinically meaningful improvement [2][5] - The trial also showed over 80% of patients achieved a clinically important improvement as per ASDAS-CRP score, with significant reductions in inflammation and osteoblast activity observed through PET imaging [2][5][6] Group 2 - MoonLake reported financial results for Q4 and the year ended December 31, 2025, with cash and equivalents totaling $394 million, expected to fund operations into the second half of 2027 [7] - Research and development expenses for Q4 2025 were $56 million, down from $60.6 million in the previous quarter, while general and administrative expenses decreased to $9.2 million from $10.8 million [7] - The company amended its debt facility with Hercules Capital, drawing down $25 million, with up to $400 million in non-dilutive funds available for future needs [7] Group 3 - An Investor Day webcast is scheduled for February 23, 2026, where the company will present the S-OLARIS data and discuss upcoming milestones, including the Type B FDA Meeting outcomes for hidradenitis suppurativa [8][12] - The company is pursuing multiple indications for sonelokimab, including hidradenitis suppurativa, psoriatic arthritis, and palmoplantar pustulosis, with significant market opportunities projected [11][27][29]

Company Overview - MoonLake Immunotherapeutics (NASDAQ: MLTX) is a clinical-stage biopharmaceutical company focused on developing innovative Nanobody therapies for inflammatory skin and joint diseases. Its main asset, sonelokimab, targets IL-17A and IL-17F to alleviate inflammation in conditions such as hidradenitis suppurativa and psoriatic arthritis [4]. Analyst Ratings - Goldman Sachs downgraded MLTX from Neutral to Sell, raising the price target to $10 from $8. The firm highlighted the advancement of sonelokimab into Phase 3 for palmoplantar pustulosis as a potential opportunity but expressed concerns about significant approvability risks in hidradenitis suppurativa due to the failure of VELA-2 to meet its primary endpoint [2]. - H.C. Wainwright increased the price target for MoonLake Immunotherapeutics to $32 from $26 while maintaining a Buy rating, noting that the outcome of the FDA Type B meeting provides a clear path toward regulatory registration [3]. Investment Considerations - While there is potential for MLTX as an investment, some analysts believe that certain AI stocks present greater upside potential with less downside risk [5].